Emerging paradigms in treating cerebral infarction with nanotheranostics: opportunities and clinical challenges

Almalki WH 1 , Alghamdi S 2 , Alzahrani A 3 , Zhang W 4

Affiliations 

  • 1 Department of Pharmacology and Toxicology, College of Pharmacy, Umm al-qura University, Saudi Arabia. Electronic address: whmalki@uqu.edu.sa
  • 2 Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-qura University, Makkah, Saudi Arabia
  • 3 Department of Pharmacology, College of Clinical Pharmacy, Albaha University, Saudi Arabia
  • 4 Senior Research Scientist, Inn Research Sdn. Bhd., Subang Jaya, Selangor, Malaysia
Drug Discov Today, 2021 03;26(3):826-835.
PMID: 33383212 DOI: 10.1016/j.drudis.2020.12.018

Abstract

Interest is increasing in the use of nanotheranostics as diagnosis, imaging and therapeutic tools for stroke management, but movement to the clinic remains challenging.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications